{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:25:03Z","timestamp":1781090703331,"version":"3.54.1"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aims to establish a random forest model for detecting the severity of\n                    Graves Orbitopathy (GO) and identify significant classification factors. This is\n                    a hospital-based study of 199 patients with GO that were collected between\n                    December 2019 and February 2022. Clinical information was collected from medical\n                    records. The severity of GO can be categorized as mild, moderate-to-severe, and\n                    sight-threatening GO based on guidelines of the European Group on Graves\u2019\n                    orbitopathy. A random forest model was constructed according to the risk factors\n                    of GO and the main ocular symptoms of patients to differentiate mild GO from\n                    severe GO and finally was compared with logistic regression analysis, Support\n                    Vector Machine (SVM), and Naive Bayes. A random forest model with 15 variables\n                    was constructed. Blurred vision, disease course, thyroid-stimulating hormone\n                    receptor antibodies, and age ranked high both in mini-decreased gini and mini\n                    decrease accuracy. The accuracy, positive predictive value, negative predictive\n                    value, and the F1 Score of the random forest model are 0.83, 0.82, 0.86, and\n                    0.82, respectively. Compared to the three other models, our random forest model\n                    showed a more reliable performance based on AUC (0.85 vs. 0.83 vs. 0.80 vs.\n                    0.76) and accuracy (0.83 vs. 0.78 vs. 0.77 vs. 0.70). In conclusion, this study\n                    shows the potential for applying a random forest model as a complementary tool\n                    to differentiate GO severity.<\/jats:p>","DOI":"10.1055\/a-2287-3734","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T22:57:41Z","timestamp":1712617061000},"page":"706-711","source":"Crossref","is-referenced-by-count":4,"title":["Severity Identification of Graves Orbitopathy via Random Forest\n                    Algorithm"],"prefix":"10.1055","volume":"56","author":[{"given":"Minghui","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing\n                    Ophthalmology and Visual Science Key Lab, Beijing, China"},{"name":"Department of Ophthalmology, Faculty of Medicine and University\n                    Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongfei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke, University of Tu\u0308bingen, Tu\u0308bingen,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Dong","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing\n                    Ophthalmology and Visual Science Key Lab, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijia","family":"Hou","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing\n                    Ophthalmology and Visual Science Key Lab, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing\n                    Ophthalmology and Visual Science Key Lab, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing\n                    Ophthalmology and Visual Science Key Lab, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice\n                    guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"L Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ando.2018.08.005","article-title":"Graves\u2019 orbitopathy: diagnosis and treatment","volume":"79","author":"D Drui","year":"2018","journal-title":"Ann Endocrinol (Paris)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves\u2019 ophthalmopathy","volume":"26","author":"L Bartalena","year":"2012","journal-title":"Best Pract Res Clin Endodrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1210\/clinem\/dgad030","article-title":"Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO\n                    multicenter European study","volume":"108","author":"F Biscarini","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"L Breiman","year":"2001","journal-title":"Mach Learn"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1471-2105-10-147","article-title":"Effects of sample size on robustness and prediction accuracy of a prognostic\n                    gene signature","volume":"10","author":"S Y Kim","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ane.13619","article-title":"Predicting the functional outcomes of anti-LGI1 encephalitis using a random\n                    forest model","volume":"146","author":"G Li","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1080\/07481187.2022.2160519","article-title":"Identifying suicide ideation in mental health application posts: a random forest\n                    algorithm","volume":"47","author":"H Moradian","year":"2023","journal-title":"Death Stud"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12859-018-2264-5","article-title":"Random Forest versus logistic regression: a large-scale benchmark\n                    experiment","volume":"19","author":"R Couronn\u00e9","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/thy.2008.0044","article-title":"Prevalence, risk factors, and clinical features of thyroid\u2011associated\n                    ophthalmopathy in multiethnic malaysian patients with Graves\u2019 disease","volume":"18","author":"S L Lim","year":"2008","journal-title":"Thyroid"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.4103\/ijo.IJO_104_20","article-title":"Clinical profile of thyroid eye disease and factors predictive of disease\n                    severity","volume":"68","author":"A Muralidhar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/eje.0.1480491","article-title":"Multi\u2011center study on the characteristics and treatment strategies of patients\n                    with Graves\u2019 orbitopathy: the first European group on Graves\u2019 orbitopathy\n                    experience","volume":"148","author":"M F Prummel","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of\n                    patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single\n                    center","volume":"98","author":"M L Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1210\/jc.2012-1275","article-title":"Incidence and clinical presentation of moderate to severe graves\u2019 orbitopathy in\n                    a Danish population before and after iodine fortification of salt","volume":"97","author":"P Laurberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy\n                    associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"G B Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves\u2019 orbitopathy in a large series of\n                    patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single\n                    center","volume":"98","author":"M L Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40618-018-0945-6","article-title":"Usefulness of TSH receptor antibodies as biomarkers for Graves\u2019 ophthalmopathy:\n                    a systematic review","volume":"41","author":"S Seo","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1013964023376","article-title":"Estimating generalization error on two-class datasets using out-of-bag\n                    estimates","volume":"48","author":"T Bylander","year":"2002","journal-title":"Mach Learn"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","article-title":"Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy","volume":"5","author":"W M Wiersinga","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019\n                    ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"A K Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.beem.2011.11.007","article-title":"Evaluating Graves\u2019 orbitopathy","volume":"26","author":"P J Dolman","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"R S Bahn","year":"2010","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1160172","DOI":"10.3389\/fendo.2023.1160172","article-title":"Influence of biological sex, age and smoking on Graves\u2019 orbitopathy \u2013 a ten-year\n                    tertiary referral center analysis","volume":"14","author":"M Oeverhaus","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cen.12222","article-title":"Smoking and thyroid","volume":"79","author":"W M Wiersinga","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves\u2019 orbitopathy","volume":"292","author":"L Bartalena","year":"2022","journal-title":"J Intern Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cxo.12472","article-title":"Thyroid eye disease: a review","volume":"100","author":"D L Weiler","year":"2017","journal-title":"Clin Exp Optom"},{"key":"ref27","first-page":"180","volume-title":"Treatment of Graves\u2019 ophthalmopathy. Tratamiento de la oftalmopat\u00eda de\n                    Graves","author":"A Gonz\u00e1lez-Garc\u00eda","year":"2021"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40265-018-1045-9","article-title":"Current and emerging treatment strategies for Graves\u2019 orbitopathy","volume":"79","author":"N Genere","year":"2019","journal-title":"drugs"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2287-3734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T15:59:51Z","timestamp":1730822391000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2287-3734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,2]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2287-3734","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]}}}